

8.2 Literatur

1. **Abbott CA, Baker E, Sutherland GR, McCaughan GW.** Genomic organization, exact localization, and tissue expression of the human CD26 (dipeptidyl peptidase IV) gene. Erratum in: *Immunogenetics* 1995;42:76. *Immunogenetics*. 1994; **40**:331-8.
2. **Abbott CA, McCaughan GW, Gorrell MD.** Two highly conserved glutamic acid residues in the predicted beta propeller domain of dipeptidyl peptidase IV are required for its enzyme activity. *FEBS Lett*. 1999; **458**:278-84.
3. **Abbott CA, McCaughan GW, Levy MT, Church WB, Gorrell MD.** Binding to human dipeptidyl peptidase IV by adenosine deaminase and antibodies that inhibit ligand binding involves overlapping, discontinuous sites on a predicted beta propeller domain. *Eur J Biochem*. 1999; **266**:798-810.
4. **Abdel-Ghany M, Cheng H, Levine RA, Pauli BU.** Truncated dipeptidyl peptidase IV is a potent anti-adhesion and anti-metastasis peptide for rat breast cancer cells. *Invasion Metastasis*. 1998; **18**:35-43.
5. **Ahmad S, Wang L, Ward PE.** Dipeptidyl(amino)peptidase IV and aminopeptidase M metabolize circulating substance P in vivo. *J Pharmacol Exp Ther*. 1992; **260**:1257-61.
6. **Ahren B, Pacini G.** Dose-related effects of GLP-1 on insulin secretion, insulin sensitivity, and glucose effectiveness in mice. *Am J Physiol*. 1999; **277**:E996-E1004.
7. **Albino AP, Sozzi G, Nanus DM, Jhanwar SC, Houghton AN.** Malignant transformation of human melanocytes: induction of a complete melanoma phenotype and genotype. *Oncogene*. 1992; **7**:2315-21.
8. **Ansorge S, Schön E.** Dipeptidyl peptidase IV (DPPIV), a functional marker of the T lymphocyte system. *Acta Histochem*. 1987; **82**:41-6.
9. **Ansorge S, Schön E, Kunz D.** Membrane-bound peptidases of lymphocytes: functional implications. *Biomed Biochim Acta*. 1991; **50**:799-807.
10. **Apasov SG, Blackburn MR, Kellems RE, Smith PT, Sitkovsky MV.** Adenosine deaminase deficiency increases thymic apoptosis and causes defective T cell receptor signaling. *J Clin Invest*. 2001; **108**:131-41.
11. **Artym VV, Kindzelskii AL, Chen WT, Petty HR.** Molecular proximity of seprase and the urokinase-type plasminogen activator receptor on malignant melanoma cell membranes: dependence on beta1 integrins and the cytoskeleton. *Carcinogenesis*. 2002; **23**:1593-601.
12. **Atherton AJ, Monaghan P, Warburton MJ, Robertson D, Kenny AJ, Gusterson BA.** Dipeptidyl peptidase IV expression identifies a functional subpopulation of breast fibroblasts. *Int J Cancer* 1992; **50**:15-19.
13. **Aytac U, Claret FX, Ho L, Sato K, Ohnuma K, Mills GB, Cabanillas F, Morimoto C, Dang NH.** Expression of CD26 and its associated dipeptidyl peptidase IV enzyme activity enhances sensitivity to doxorubicin-induced cell cycle arrest at the G(2)/M checkpoint. *Cancer Res*. 2001; **61**:7204-10.
14. **Aytac U, Sato K, Yamochi T, Yamochi T, Ohnuma K, Mills GB, Morimoto C, Dang NH.** Effect of CD26/dipeptidyl peptidase IV on Jurkat sensitivity to G2/M arrest induced by topoisomerase II inhibitors. *Br J Cancer*. 2003 Feb 10; **88**:455-62.
15. **Bauvois B.** A collagen-binding glycoprotein on the surface of mouse fibroblasts is identified as dipeptidyl peptidase IV. *Biochem J*. 1988; **252**:723-31.
16. **Bella AM Jr, Erickson RH, Kim YS.** Rat intestinal brush border membrane dipeptidyl-aminopeptidase IV: kinetic properties and substrate specificities of the purified enzyme. *Arch Biochem Biophys*. 1982; **218**:156-62.
17. **Bermphohl F, Löster K, Reutter W, Baum O.** Rat dipeptidyl peptidase IV (DPP IV) exhibits endopeptidase activity with specificity for denatured fibrillar collagens. *FEBS Lett*. 1998; **428**:152-6.
18. **Birnboim HC, Doly J.** A rapid alkaline extraction procedure for screening recombinant plasmid DNA. *Nucleic Acids Res*, **7**, 1513-23, 1979.

19. **Blanco J, Valenzuela A, Herrera C, Lluís C, Hovanessian AG, Franco R.** The HIV-1 gp120 inhibits the binding of adenosine deaminase to CD26 by a mechanism modulated by CD4 and CXCR4 expression. *FEBS Lett.* 2000; **477**:123-8.
20. **Blazquez MV, Madueno JA, Gonzalez R, Jurado R, Bachovchin WW, Pena J, Munoz E.** Selective decrease of CD26 expression in T cells from HIV-1-infected individuals. *J Immunol.* 1992; **149**:3073-7.
21. **Bongers J, Lambros T, Ahmad M, Heimer EP.** Kinetics of dipeptidyl peptidase IV proteolysis of growth hormone-releasing factor and analogs. *Biochim Biophys Acta.* 1992; **1122**:147-53.
22. **Brandt W.** Development of a tertiary-structure model of the C-terminal domain of DPP IV. *Adv Exp Med Biol.* 2000; **477**:97-101.
23. **Bristol LA, Sakaguchi K, Appella E, Doyle D, Takacs L.** Thymocyte costimulating antigen is CD26 (dipeptidyl-peptidase IV). Costimulation of granulocyte, macrophage, and T lineage cell proliferation via CD26. *J Immunol.* 1992; **149**:367-72.
24. **Brostrom C, Sonnerborg A, Lindback S, Gaines H.** Low relative frequencies of CD26(+) CD4(+) cells in long-term nonprogressing human immunodeficiency virus type 1-infected subjects. *Clin Diagn Lab Immunol.* 1998; **5**:662-6.
25. **Bruggen J, Macher E, Sorg C.** Expression of surface antigens and its relation to parameters of malignancy in human malignant melanoma. *Cancer Immunol Immunother.* 1981; **10**:121-127.
26. **Buc HA, Moncion A, Hamet M, Houllier AM, Thuillier L, Perignon JL.** Influence of adenosine deaminase inhibition on the phosphoinositide turnover in the initial stages of human T cell activation. *Eur J Immunol.* 1990; **20**:611-5.
27. **Buhling F, Kunz D, Reinhold D, Ulmer AJ, Ernst M, Flad HD, Ansorge S.** Expression and functional role of dipeptidyl peptidase IV (CD26) on human natural killer cells. *Nat Immun.* 1994; **13**:270-9.
28. **Callebaut C, Jacotot E, Blanco J, Krust B, Hovanessian AG.** Increased rate of HIV-1 entry and its cytopathic effect in CD4+/CXCR4+ T cells expressing relatively high levels of CD26. *Exp Cell Res.* 1998; **241**:352-62.
29. **Callebaut C, Krust B, Jacotot E, Hovanessian AG.** T cell activation antigen, CD26, as a cofactor for entry of HIV in CD4+ cells. *Science.* 1993; **262**:2045-50.
30. **Carbone A, Gloghini A, Zagonel V, Aldinucci D, Gattei V, Degan M, Improta S, Sorio R, Monfardini S, Pinto A.** The expression of CD26 and CD40 ligand is mutually exclusive in human T-cell non-Hodgkin's lymphomas/leukemias. *Blood.* 1995; **86**:4617-26.
31. **Cheng HC, Abdel-Ghany M, Elble RC, Pauli BU.** Lung endothelial dipeptidyl peptidase IV promotes adhesion and metastasis of rat breast cancer cells via tumor cell surface-associated fibronectin. *J Biol Chem.* 1998; **273**:24207-15.
32. **Cheng HC, Abdel-Ghany M, Pauli BU.** A novel consensus motif in fibronectin mediates dipeptidyl peptidase IV adhesion and metastasis. *J Biol Chem.* 2003; **278**:24600-7.
33. **Cheng HC, Abdel-Ghany M, Zhang S, Pauli BU.** Is the Fischer 344/CRJ rat a protein-knock-out model for dipeptidyl peptidase IV-mediated lung metastasis of breast cancer? *Clin Exp Metastasis.* 1999; **17**:609-15.
34. **Chien J, Wong E, Nikes E, Noble MJ, Pantazis CG and Shah GV** Constitutive activation of stimulatory guanine nucleotide binding protein (GSQL)-mediated signaling increases invasiveness and tumorigenicity of PC-3M prostate cancer cells *Oncogene* 1999; **18**: 3376-3382.
35. **Choe H, Farzan M, Sun Y, Sullivan N, Rollins B, Ponath PD, Wu L, Mackay CR, LaRosa G, Newman W, Gerard N, Gerard C, Sodroski J.** The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. *Cell.* 1996; **85**:1135-48.
36. **Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P.** Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. *Science.* 1995; **270**:1811-5.
37. **Conarello SL, Li Z, Ronan J, Roy RS, Zhu L, Jiang G, Liu F, Woods J, Zycband E, Möller DE, Thornberry NA, Zhang BB.** Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance. *Proc Natl Acad Sci U S A.* 2003; **100**:6825-30.
38. **Cordero OJ, Ayude D, Nogueira M, Rodriguez-Berrocal FJ, de la Cadena MP.** Preoperative serum CD26 levels: diagnostic efficiency and predictive value for colorectal cancer. *Br J Cancer.* 2000; **83**:1139-1146.

39. **Daddona PE, Kelley WN.** Human adenosine deaminase binding protein. Assay, purification, and properties. *J Biol Chem.* 1978; **253**:4617-23.
40. **Dai J, Shen R, Sumitomo M, Goldberg JS, Geng Y, Navarro D, Xu S, Koutcher JA, Garzotto M, Powell CT, Nanus DM.** Tumor-suppressive effects of neutral endopeptidase in androgen-independent prostate cancer cells. *Clin Cancer Res.* 2001; **7**:1370-7.
41. **Dang NH, Hagemester FB, Duvic M, Romaguera JE, Younes A, Jones D, Samuels B, Fayad LE, Pro B, Samaniego F, Sarris A, Goy A, McLaughlin P, Tong AT, Walker PL, Tiongson LP, Smith TL, Huh YO, Morimoto C, Rodriguez MA.** Pentostatin in T-non-Hodgkin's lymphomas: efficacy and effect on CD26+ T lymphocytes. *Oncol Rep.* 2003; **10**:1513-8.
42. **Dang NH, Torimoto Y, Deusch K, Schlossman SF, Morimoto C.** Comitogenic effect of solid-phase immobilized anti-1F7 on human CD4 T cell activation via CD3 and CD2 pathways. *J Immunol.* 1990; **144**:4092-100.
43. **Dang NH, Torimoto Y, Schlossman SF, Morimoto C.** Human CD4 helper T cell activation: functional involvement of two distinct collagen receptors, 1F7 and VLA integrin family. *J Exp Med.* 1990; **172**:649-52.
44. **Dang NH, Torimoto Y, Shimamura K, Tanaka T, Daley JF, Schlossman SF, Morimoto C.** 1F7 (CD26): a marker of thymic maturation involved in the differential regulation of the CD3 and CD2 pathways of human thymocyte activation. *J Immunol.* 1991; **147**:2825-32.
45. **Dang NH, Torimoto Y, Sugita K, Daley JF, Schow P, Prado C, Schlossman SF, Morimoto C.** Cell surface modulation of CD26 by anti-1F7 monoclonal antibody. Analysis of surface expression and human T cell activation. *J Immunol.* 1990; **145**:3963-71.
46. **Darmoul D, Fox M, Harvey C, Jeggo P, Gum JR, Kim YS, Swallow DM.** Regional localization of DPP4 (alias CD26 and ADCP2) to chromosome 2q24. *Somat Cell Mol Genet.* 1994; **20**:345-51.
47. **Darmoul D, Lacasa M, Baricault L, Marguet D, Sapin C, Trotot P, Barbat A, Trugnan G.** Dipeptidyl peptidase IV (CD 26) gene expression in enterocyte-like colon cancer cell lines HT-29 and Caco-2. Cloning of the complete human coding sequence and changes of dipeptidyl peptidase IV mRNA levels during cell differentiation. *J Biol Chem.* 1992; **267**:4824-33.
48. **David F, Bernard AM, Pierres M, Marguet D.** Identification of serine 624, aspartic acid 702, and histidine 734 as the catalytic triad residues of mouse dipeptidyl-peptidase IV (CD26). A member of a novel family of nonclassical serine hydrolases. *J Biol Chem.* 1993; **268**:17247-52.
49. **Deacon CF., Holst JJ.** Dipeptidyl peptidase IV inhibition as an approach to the treatment and prevention of type 2 diabetes: a historical perspective *Biochemical and Biophysical Research Communications* 2002; **294**:1-4.
50. **De Meester I, Korom S, Van Damme J, Scharpe S.** CD26, let it cut or cut it down. *Immunol Today.* 1999; **20**:367-75.
51. **De Meester I, Vanham G, Kestens L, Vanhoof G, Bosmans E, Gigase P, Scharpe S.** Binding of adenosine deaminase to the lymphocyte surface via CD26. *Eur J Immunol.* 1994; **24**:566-70.
52. **Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Marzio P, Marmon S, Sutton RE, Hill CM, Davis CB, Peiper SC, Schall TJ, Littman DR, Landau NR.** Identification of a major co-receptor for primary isolates of HIV-1. *Nature.* 1996; **381**:661-6.
53. **De Pasquale A, Ginaldi L, Limoncelli P, Quaglino D.** Dipeptidyl amino peptidase IV cytochemistry in circulating lymphocytes from HIV-I-seropositive subjects. *Acta Haematol.* 1989; **81**:19-21.
54. **Dinjens WN, ten Kate J, Wijnen JT, van der Linden EP, Beek CJ, Lenders MH, Khan PM, Bosman FT.** Distribution of adenosine deaminase-complexing protein in murine tissues. *J Biol Chem.* 1989; **264**:19215-20.
55. **Dobers Jörg, Grams Sabine, Reutter Werner and Fan Hua.** Roles of cysteines in rat dipeptidyl peptidase IV/CD26 in processing and proteolytic activity. *Eur. J. Biochem.* 2000; **267**:5093-5100.
56. **Dong RP, Kameoka J, Hegen M, Tanaka T, Xu Y, Schlossman SF, Morimoto C.** Characterization of adenosine deaminase binding to human CD26 on T cells and its biologic role in immune response. *J Immunol.* 1996; **156**:1349-55.
57. **Dong RP, Tachibana K, Hegen M, Munakata Y, Cho D, Schlossman SF, Morimoto C.** Determination of adenosine deaminase binding domain on CD26 and its immunoregulatory effect on T cell activation. *J Immunol.* 1997; **159**:6070-6.

58. **Doumas A, van den Broek P, Affolter M, Monod M.** Characterization of the prolyl dipeptidyl peptidase gene (dppIV) from the koji mold *Aspergillus oryzae*. *Appl Environ Microbiol.* 1998; **64**:4809-15.
59. **Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA, Cayanan C, Maddon PJ, Koup RA, Moore JP, Paxton WA.** HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. *Nature.* 1996; **381**:667-73.
60. **Duke-Cohan JS, Morimoto C, Rocker JA, Schlossman SF.** A novel form of dipeptidylpeptidase IV found in human serum. Isolation, characterization, and comparison with T lymphocyte membrane dipeptidylpeptidase IV (CD26). *J Biol Chem.* 1995; **270**:14107-14.
61. **Durinx C, Lambeir AM, Bosmans E, Falmagne JB, Berghmans R, Haemers A, Scharpe S, De Meester I.** Molecular characterization of dipeptidyl peptidase activity in serum: soluble CD26/dipeptidyl peptidase IV is responsible for the release of X-Pro dipeptides. *Eur J Biochem.* 2000; **267**:5608-13.
62. **Eguchi K, Ueki Y, Shimomura C, Otsubo T, Nakao H, Migita K, Kawakami A, Matsunaga M, Tezuka H, Ishikawa N, et al.** Increment in the Ta1+ cells in the peripheral blood and thyroid tissue of patients with Graves' disease. *J Immunol.* 1989; **142**:4233-40.
63. **Fan Hua, Meng Wenmao, Kilian Christiane, Grams Sabine, Reutter Werner.** Domain-specific N-glycosylation of the membrane glycoprotein dipeptidylpeptidase IV (CD26) influences its subcellular trafficking, biological stability, enzyme activity and protein folding. *Eur. J. Biochem.* 1997; **246**:243-251.
64. **Fan Hua, Yan Shuling, Stehling Sabine, Marguet Didier, Schuppan Detlef and Reutter Werner.** Dipeptidyl Peptidase IV/CD26 in T Cell Activation, Cytokine Secretion and Immunoglobulin Production. *Dipeptidyl Aminopeptidases in Health and Disease*, Edited by Hildebrandt et al., Kluwer Academic/Plenum Publ., New York, 2003-12-13
65. **Fleischer B.** A novel pathway of human T cell activation via a 103 kD T cell activation antigen. *J Immunol.* 1987; **138**:1346-50.
66. **Fleischer B.** CD26: a surface protease involved in T-cell activation. *Immunol Today.* 1994; **15**:180-4.
67. **Fleischer B, Sturm E, De Vries JE, Spits H.** Triggering of cytotoxic T lymphocytes and NK cells via the Tp103 pathway is dependent on the expression of the T cell receptor/CD3 complex. *J Immunol.* 1988; **141**:1103-7.
68. **Flentke GR, Munoz E, Huber BT, Plaut AG, Kettner CA, Bachovchin WW.** Inhibition of dipeptidyl aminopeptidase IV (DP-IV) by Xaa-boroPro dipeptides and use of these inhibitors to examine the role of DP-IV in T-cell function. *Proc Natl Acad Sci U S A.* 1991; **88**:1556-9.
69. **Fountain JW, Bale SJ, Housman DE, Dracopoli NC.** Genetics of melanoma. *Cancer Surv.* 1990; **9**:645-71.
70. **Fox DA, Hussey RE, Fitzgerald KA, Acuto O, Poole C, Palley L, Daley JF, Schlossman SF, Reinherz EL.** Ta1, a novel 105 KD human T cell activation antigen defined by a monoclonal antibody. *J Immunol.* 1984; **133**:1250-6.
71. **Franco R, Valenzuela A, Lluís C, Blanco J.** Enzymatic and extraenzymatic role of ecto-adenosine deaminase in lymphocytes. *Immunol Rev.* 1998; **161**:27-42.
72. **Fulop V, Bocskei Z, Polgar L.** Prolyl oligopeptidase: an unusual beta-propeller domain regulates proteolysis. *Cell.* 1998; **94**:161-70.
73. **Gaetaniello L, Fiore M, de Filippo S, Pozzi N, Tamasi S, Pignata C.** Occupancy of dipeptidyl peptidase IV activates an associated tyrosine kinase and triggers an apoptotic signal in human hepatocarcinoma cells. *Hepatology.* 1998; **27**:934-42.
74. **Garzino-Demo A, DeVico AL, Conant KE, Gallo RC.** The role of chemokines in human immunodeficiency virus infection. *Immunol Rev.* 2000; **177**:79-87.
75. **Geppert TD, Davis LS, Gur H, Wacholtz MC, Lipsky PE.** Accessory cell signals involved in T-cell activation. *Immunol Rev.* 1990; **117**:5-66.
76. **Gherzi G, Dong H, Goldstein LA, Yeh Y, Hakkinen L, Larjava HS, Chen WT.** Regulation of fibroblast migration on collagenous matrix by a cell surface peptidase complex. *J Biol Chem.* 2002; **277**:29231-41.

77. **Goldstein L.A., Gherzi G., Piñeiro-Sánchez M.L., Salamone M., Yeh Y., Flessate D. and Chen W-T.** Molecular cloning of seprase: a serine integral membrane protease from human melanoma. *Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease* 1997; **1361**(1): 11-19
78. **Gonzalez-Gronow M, Grenett HE, Weber MR, Gawdi G, Pizzo SV.** Interaction of plasminogen with dipeptidyl peptidase IV initiates a signal transduction mechanism which regulates expression of matrix metalloproteinase-9 by prostate cancer cells. *Biochem J.* 2001; **355**:397-407.
79. **Gorrell MD, Abbott CA, Kahne T, Levy MT, Church WB, McCaughan GW.** Relating structure to function in the beta-propeller domain of dipeptidyl peptidase IV. Point mutations that influence adenosine deaminase binding, antibody binding and enzyme activity. *Adv Exp Med Biol.* 2000; **477**:89-95.
80. **Gorrell MD, Gysbers V, McCaughan GW.** CD26: a multifunctional integral membrane and secreted protein of activated lymphocytes. *Scand J Immunol.* 2001; **54**:249-64.
81. **Gougeon ML, Lecoœur H, Callebaut C, Jacotot E, Dulioust A, Roue R, Montagnier L, Hovanessian AG.** Selective loss of the CD4+/CD26+ T-cell subset during HIV infection. *Res Immunol.* 1996; **147**:5-8.
82. **Grodin G, Hooper NM, LeBel D.** Specific localization of membrane dipeptidase and dipeptidyl peptidase IV in secretion granules of two different pancreatic islet cells. *J Histochem Cytochem* 1999; **47**:489-498.
83. **Gutheil WG, Subramanyam M, Flentke GR, Sanford DG, Munoz E, Huber BT, Bachovchin WW.** Human immunodeficiency virus 1 Tat binds to dipeptidyl aminopeptidase IV (CD26): a possible mechanism for Tat's immunosuppressive activity. *Proc Natl Acad Sci U S A.* 1994; **91**:6594-8.
84. **Hafler DA, Fox DA, Manning ME, Schlossman SF, Reinherz EL, Weiner HL.** In vivo activated T lymphocytes in the peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. *N Engl J Med.* 1985; **312**:1405-11.
85. **Hanski, C; Huhle, T; Gossrau, R; Reutter, W** Direct evidence for the binding of rat liver DPP IV to collagen in vitro *Experimental Cell Research* 1988; **178**:64-72.
86. **Hanski C, Huhle T, Reutter W.** Involvement of plasma membrane dipeptidyl peptidase IV in fibronectin-mediated adhesion of cells on collagen. *Biol Chem Hoppe Seyler.* 1985; **366**:1169-76.
87. **Hanski C, Zimmer T, Gossrau R, Reutter W.** Increased activity of dipeptidyl peptidase IV in serum of hepatoma-bearing rats coincides with the loss of the enzyme from the hepatoma plasma membrane. *Experientia.* 1986; **42**(7):826-8.
88. **Hashimoto, F. et al.** An improved method for separation of low-molecular weight polypeptides by electrophoresis in sodium dodecyl sulfate-polyacrylamide gel. *Anal. Biochem.* 1983; **129**:192-199.
89. **Hegen M, Kameoka J, Dong RP, Schlossman SF, Morimoto C.** Cross-linking of CD26 by antibody induces tyrosine phosphorylation and activation of mitogen-activated protein kinase. *Immunology.* 1997; **90**:257-64.
90. **Hegen M, Mittrucker HW, Hug R, Demuth HU, Neubert K, Barth A, Fleischer B.** Enzymatic activity of CD26 (dipeptidylpeptidase IV) is not required for its signalling function in T cells. *Immunobiology.* 1993; **189**:483-93.
91. **Herrera C, Morimoto C, Blanco J, Mallol J, Arenzana F, Lluís C, Franco R.** Comodulation of CXCR4 and CD26 in human lymphocytes. *J Biol Chem.* 2001; **276**:19532-9.
92. **Heymann E, Mentlein R.** Liver dipeptidyl aminopeptidase IV hydrolyzes substance P. *FEBS Lett.* 1978; **91**:360-4.
93. **Hirschhorn R.** Adenosine deaminase deficiency. *Immunodeficiency Rev.* 1990; **2**:175-98.
94. **Ho L, Aytac U, Stephens LC, Ohnuma K, Mills GB, McKee KS, Neumann C, LaPushin R, Cabanillas F, Abbruzzese JL, Morimoto C, Dang NH.** In vitro and in vivo antitumor effect of the anti-CD26 monoclonal antibody 1F7 on human CD30+ anaplastic large cell T-cell lymphoma Karpas 299. *Clin Cancer Res.* 2001; **7**:2031-40.
95. **Hoffmann T, Faust J, Neubert K, Ansoerge S.** Dipeptidyl peptidase IV (CD 26) and aminopeptidase N (CD 13) catalyzed hydrolysis of cytokines and peptides with N-terminal cytokine sequences. *FEBS Lett.* 1993; **336**:61-4.
96. **Hong W, Doyle D.** cDNA cloning for a bile canaliculus domain-specific membrane glycoprotein of rat hepatocytes. *Proc Natl Acad Sci U S A.* 1987; **84**:7962-6.

97. **Hong WJ, Doyle D.** Membrane orientation of rat gp110 as studied by in vitro translation. *J Biol Chem.* 1988; **263**:16892-8.
98. **Hong WJ, Doyle D.** Molecular dissection of the NH₂-terminal signal/anchor sequence of rat dipeptidyl peptidase IV. *J Cell Biol.* 1990; **111**:323-8.
99. **Hopsu-Havu VK, Glenner GG.** A new dipeptide naphthylamidase hydrolysing glycyl-prolyl- β -naphthylamide. *Histochem.* 1966; **7**:197-201.
100. **Hosono O, Homma T, Kobayashi H, Munakata Y, Nojima Y, Iwamoto A, Morimoto C.** Decreased dipeptidyl peptidase IV enzyme activity of plasma soluble CD26 and its inverse correlation with HIV-1 RNA in HIV-1 infected individuals. *Clin Immunol.* 1999; **91**:283-95.
101. **Houghton AN, Albino AP, Cordon-Cardo C, Davis LJ, Eisinger M.** Cell surface antigens of human melanocytes and melanoma. Expression of adenosine deaminase binding protein is extinguished with melanocyte transformation. *J Exp Med.* 1988; **167**:197-212.
102. **Huber MA, Kraut N, Park JE, Schubert RD, Rettig WJ, Peter RU, Garin-Chesa P.** Fibroblast activation protein: differential expression and serine protease activity in reactive stromal fibroblasts of melanocytic skin tumors. *J Invest Dermatol.* 2003; **120**:182-8.
103. **Huhn J, Olek S, Fleischer B, von Bonin A.** The adenosine deaminase-binding region is distinct from major anti-CD26 mAb epitopes on the human dipeptidyl peptidase IV(CD26) molecule. *Cell Immunol.* 1999; **192**:33-40.
104. **Hutchinson DR, Halliwell RP, Lockhart JD, Parke DV.** Glycylprolyl-p-nitroanilidase in hepatobiliary disease. *Clin Chim Acta.* 1981; **109**:83-9.
105. **Ish-Horowicz D, Burke JF.** Rapid and efficient cosmid cloning. *Nucleic Acids Res.* 1981; **9**:2989-98.
106. **Ishii T, Ohnuma K, Murakami A, Takasawa N, Kobayashi S, Dang NH, Schlossman SF, Morimoto C.** CD26-mediated signaling for T cell activation occurs in lipid rafts through its association with CD45RO. *Proc Natl Acad Sci U S A.* 2001; **98**:12138-43.
107. **Iwaki-Egawa S, Watanabe Y, Fujimoto Y.** CD26/dipeptidyl peptidase IV does not work as an adenosine deaminase-binding protein in rat cells. *Cell Immunol.* 1997; **178**:180-6.
108. **Iwata S, Yamaguchi N, Munakata Y, Ikushima H, Lee JF, Hosono O, Schlossman SF, Morimoto C.** CD26/dipeptidyl peptidase IV differentially regulates the chemotaxis of T cells and monocytes toward RANTES: possible mechanism for the switch from innate to acquired immune response. *Int Immunol.* 1999; **11**:417-26.
109. **Iyengar S, Hildreth JE, Schwartz DH** Actin-dependent receptor colocalization required for human immunodeficiency virus entry into host cells *J Virol.* 1998; **72**:5251-5.
110. **Jiang JD, Wilk S, Li J, Zhang H, Bekesi JG.** Inhibition of human immunodeficiency virus type 1 infection in a T-cell line (CEM) by new dipeptidyl-peptidase IV (CD26) inhibitors. *Res Virol.* 1997; **48**:255-66.
111. **Johnson RC, Zhu D, Augustin-Voss HG, Pauli BU.** Lung endothelial dipeptidyl peptidase IV is an adhesion molecule for lung-metastatic rat breast and prostate carcinoma cells. *J Cell Biol.* 1993; **121**:1423-32.
112. **Kahne T, Neubert K, Ansorge S.** Enzymatic activity of DPIV/CD26 is involved in PMA-induced hyperphosphorylation of p56lck. *Immunol Lett.* 1995; **46**:189-93.
113. **Kahne T, Neubert K, Faust J, Ansorge S.** Early phosphorylation events induced by DPIV/CD26-specific inhibitors. *Cell Immunol.* 1998; **189**:60-6.
114. **Kajiyama H, Kikkawa F, Khin E, Shibata K, Ino K, Mizutani S.** Dipeptidyl peptidase IV overexpression induces up-regulation of E-cadherin and tissue inhibitors of matrix metalloproteinases, resulting in decreased invasive potential in ovarian carcinoma cells. *Cancer Res.* 2003; **63**:2278-83.
115. **Kajiyama H, Kikkawa F, Suzuki T, Shibata K, Ino K, Mizutani S.** Prolonged survival and decreased invasive activity attributable to dipeptidyl peptidase IV overexpression in ovarian carcinoma. *Cancer Res.* 2002; **62**:2753-7.
116. **Kameoka J, Tanaka T, Nojima Y, Schlossman SF, Morimoto C.** Direct association of adenosine deaminase with a T cell activation antigen, CD26. *Science.* 1993; **261**:466-9.
117. **Kenny AJ, Booth AG, George SG, Ingram J, Kershaw D, Wood EJ, Young AR.** Dipeptidyl peptidase IV, a kidney brush-border serine peptidase. *Biochem J.* 1976; **157**:169-82.

118. **Khin EE, Kikkawa F, Ino K, Kajiyama H, Suzuki T, Shibata K, Tamakoshi K, Nagasaka T, Mizutani S.** Dipeptidyl peptidase IV expression in endometrial endometrioid adenocarcinoma and its inverse correlation with tumor grade. *Am J Obstet Gynecol.* 2003; **188**:670-6.
119. **Kiely JM, Noh JH, Graewin SJ, Svatek CL, Pitt HA, Swartz-Basile DA.** Leptin-deficient obese mice have altered intestinal metabolic enzyme activities. *J Surg Res.* 2003; **114**:291-2.
120. **Kikkawa F, Kajiyama H, Ino K, Shibata K, Mizutani S.** Increased adhesion potency of ovarian carcinoma cells to mesothelial cells by overexpression of dipeptidyl peptidase IV. *Int J Cancer.* 2003; **105**:779-83.
121. **Kikuchi M, Fukuyama K, Epstein WL.** Soluble dipeptidyl peptidase IV from terminal differentiated rat epidermal cells: purification and its activity on synthetic and natural peptides. *Arch Biochem Biophys.* 1988; **266**:369-76.
122. **Kiyama M, Hayakawa M, Shiroza T, Nakamura S, Takeuchi A, Masamoto Y, Abiko Y.** Sequence analysis of the *Porphyromonas gingivalis* dipeptidyl peptidase IV gene. *Biochim Biophys Acta.* 1998; **1396**:39-46.
123. **Klatzmann D, Champagne E, Chamaret S, Gruest J, Guetard D, Hercend T, Gluckman JC, Montagnier L.** T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. *Nature.* 1984-1985; **312**:767-8.
124. **Kojima J, Ueno Y, Kasugai H, Okuda S, Akedo H.** Glycylproline dipeptidyl aminopeptidase and γ -glutamyl transpeptidase in human hepatic cancer and embryonal tissues. *Clin Chim Acta* 1987; **167**:285-291.
125. **Kotani T, Aratake A, Ogata Y, Umeki K, Araki Y, Hirai K, Kuma K, Ohtaki S.** Expression of dipeptidyl aminopeptidase IV activity in thyroid carcinoma. *Cancer Lett* 1991; **57**:203-208.
126. **Kreil G, Umbach M, Brantl V, Teschemacher H.** Studies on the enzymatic degradation of beta-casomorphins. *Life Sci.* 1983; **33** Suppl 1:137-40.
127. **Kreisel W, Heussner R, Volk B, Büchsel R, Reutter W, Gerok W.** Identification of the 110000Mr glycoprotein isolated from rat liver plasma membrane as dipeptidylaminopeptidase IV. *FEBS Lett.* 1982; **147**: 85-8.
128. **Krepela E, Viccar J, Zizkova L, Kasafirek E, Kolar Z, Lichnovsky V.** Dipeptidylpeptidase IV in mammalian lungs. *Lung.* 1985; **163**:33-54.
129. **Lambeir AM, Durinx C, Proost P, Van Damme J, Scharpe S, De Meester I.** Kinetic study of the processing by dipeptidyl-peptidase IV/CD26 of neuropeptides involved in pancreatic insulin secretion. *FEBS Lett* 2002; **512**:353.
130. **Lambeir AM, Durinx C, Scharpe S, De Meester I.** Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. *Crit Rev Clin Lab Sci.* 2003; **40**:209-94.
131. **Lambeir AM, Proost P, Durinx C, Bal G, Senten K, Augustyns K, Scharpe S, Van Damme J, De Meester I.** Kinetic investigation of chemokine truncation by CD26/dipeptidyl peptidase IV reveals a striking selectivity within the chemokine family. *J Biol Chem.* 2001; **276**:29839-45.
132. **Lämmlli UK.** Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature.* 1970; **227**:680-5.
133. **Lapadula G, Iannone F, Zuccaro C, Covelli M, Patella V, Lobianco G, Pipitone V.** Expression of membrane-bound peptidases (CD10 and CD26) on human articular chondrocytes. Possible role of neuropeptidases in the pathogenesis of osteoarthritis. *Clin Exp Rheumatol.* 1995; **13**:143-8.
134. **Laura Pala, Edoardo Mannucci, Anna Pezzatini, Silvia Ciania, Jacopo Sardic, Laura Raimondid, Agostino Ognibene, Angela Cappadonna, Barbara G. Vannellif and Carlo M. Rotella,** Dipeptidyl peptidase-IV expression and activity in human glomerular endothelial cells *Biochemical and Biophysical Research Communications* 2003; **310**:28-31.
135. **Li L, Price JE, Fan D, Zhang RD, Bucana CD, Fidler IJ.** Correlation of growth capacity of human tumor cells in hard agarose with their in vivo proliferative capacity at specific metastatic sites. *J Natl Cancer Inst.* 1989; **81**:1406-12.
136. **Lockshin A, Giovanella BC, De Ipolyi PD, Williams LJ, Jr., Mendoza JT, Yim SO, Stehlin JSJ.** Exceptional lethality for nude mice of cells derived from a primary human melanoma. *Cancer Res.* 1985; **45**:345-350.
137. **Löster K, Zeilinger K, Schuppan D, Reutter W.** The cysteine-rich region of dipeptidyl peptidase IV (CD 26) is the collagen-binding site. *Biochem Biophys Res Commun.* 1995; **217**:341-8.

138. **Ludwig K, Yan S, Fan H, Reutter W, Böttcher C.** The 3D structure of rat DPPIV/CD26 as obtained by cryo-TEM and single particle analysis. *Biochem Biophys Res Commun.* 2003; **304**:73-7.
139. **Lynch BJ, Guinee DG Jr, Holden JA.** Human DNA topoisomerase II-alpha: a new marker of cell proliferation in invasive breast cancer. *Hum Pathol.* 1997; **28**:1180-8.
140. **Marguet D, Bernard AM, Vivier I, Darmoul D, Naquet P, Pierres M.** cDNA cloning for mouse thymocyte-activating molecule. A multifunctional ecto-dipeptidyl peptidase IV (CD26) included in a subgroup of serine proteases. *J Biol Chem.* 1992; **267**:2200-8.
141. **Martin RA, Cleary DL, Guido DM, Zurcher-Neely HA, Kubiak TM.** Dipeptidyl peptidase IV (DPP-IV) from pig kidney cleaves analogs of bovine growth hormone-releasing factor (bGRF) modified at position 2 with Ser, Thr or Val. Extended DPP-IV substrate specificity? *Biochim Biophys Acta.* 1993; **1164**:252-60.
142. **Mattern T, Reich C, Schönbeck U, Ansorge S, Demuth HU, Loppnow H, Ulmer AJ, Flad HD.** CD26 (dipeptidyl peptidase i.v.) on human T lymphocytes does not mediate adhesion of these cells to endothelial cells or fibroblasts. *Immunobiology.* 1998; **198**:465-75.
143. **Medeiros MS, Turner AJ.** Post-secretory processing of regulatory peptides: the pancreatic polypeptide family as a model example. *Biochimie.* 1994; **76**:283-7.
144. **Mentlein R.** Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptides. *Regul Pept.* 1999; **85**:9-24.
145. **Mentlein R, Dahms P, Grandt D, Krüger R.** Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV. *Regul Pept.* 1993; **49**:133-44.
146. **Mittrucker HW, Steeg C, Malissen B, Fleischer B.** The cytoplasmic tail of the T cell receptor zeta chain is required for signaling via CD26. *Eur J Immunol.* 1995; **25**:295-7.
147. **Mizokami A, Eguchi K, Kawakami A, Ida H, Kawabe Y, Tsukada T, Aoyagi T, Maeda K, Morimoto C, Nagataki S.** Increased population of high fluorescence 1F7 (CD26) antigen on T cells in synovial fluid of patients with rheumatoid arthritis. *J Rheumatol.* 1996; **23**:2022-6.
148. **Monsky WL, Lin CY, Aoyama A, Kelly T, Akiyama SK, Mueller SC, Chen WT.** A potential marker protease of invasiveness, seprase, is localized on invadopodia of human malignant melanoma cells. *Cancer Res.* 1994; **54**:5702-10.
149. **Morimoto C, Lord CI, Zhang C, Duke-Cohan JS, Letvin NL, Schlossman SF.** Role of CD26/dipeptidyl peptidase IV in human immunodeficiency virus type 1 infection and apoptosis. *Proc Natl Acad Sci U S A.* 1994; **91**:9960-4.
150. **Morimoto C, Schlossman SF.** The structure and function of CD26 in the T-cell immune response. *Immunol Rev.* 1998; **161**:55-70.
151. **Morimoto C, Torimoto Y, Levinson G, Rudd CE, Schrieber M, Dang NH, Letvin NL, Schlossman SF.** 1F7, a novel cell surface molecule, involved in helper function of CD4 cells. *J Immunol.* 1989; **143**:3430-9 (Erratum in: *J Immunol* 1990; **144**:2027).
152. **Morrison ME, Vijayasradhi S, Engelstein D, Albino AP, Houghton AN.** A marker for neoplastic progression of human melanocytes is a cell surface ectopeptidase. *J Exp Med.* 1993; **177**:1135-43.
153. **Müller SC, Gherzi G, Akiyama SK, Sang QX, Howard L, Pineiro-Sanchez M, Nakahara H, Yeh Y, Chen WT.** A novel protease-docking function of integrin at invadopodia. *J Biol Chem.* 1999; **274**:24947-52.
154. **Munoz E, Blazquez MV, Madueno JA, Rubio G, Pena J.** CD26 induces T-cell proliferation by tyrosine protein phosphorylation. *Immunology.* 1992; **77**:43-50.
155. **Mustelin T, Coggeshall KM, Altman A.** Rapid activation of the T-cell tyrosine protein kinase pp56lck by the CD45 phosphotyrosine phosphatase. *Proc Natl Acad Sci U S A.* 1989; **86**:6302-6.
156. **Nagakura T, Yasuda N, Yamazaki K, Ikuta H, Yoshikawa S, Asano O, Tanaka I.** Improved tolerance via enhanced glucose-dependent insulin secretion in dipeptidyl peptidase IV-deficient Fischer rats. *Biochem Biophys Res Commun.* 2001; **284**:501-6.
157. **Nagatsu T, Hino M, Fuyamada H, Hayakawa T, Sakakibara S.** New chromogenic substrates for X-prolyl dipeptidyl-aminopeptidase. *Anal Biochem.* 1976; **74**:466-76.
158. **Nakahara H, Nomizu M, Akiyama SK, Yamada Y, Yeh Y, Chen WT.** A mechanism for regulation of melanoma invasion. Ligation of alpha6beta1 integrin by laminin G peptides. *J Biol Chem.* 1996; **271**:27221-4.

159. **Nakao H, Eguchi K, Kawakami A, Migita K, Otsubo T, Ueki Y, Shimomura C, Tezuka H, Matsunaga M, Maeda K, et al.** Increment of Tal positive cells in peripheral blood from patients with rheumatoid arthritis. *J Rheumatol.* 1989; **16**:904-10.
160. **Nausch I, Mentlein R, Heymann E.** The degradation of bioactive peptides and proteins by dipeptidyl peptidase IV from human placenta. *Biol Chem Hoppe Seyler.* 1990; **371**:1113-8.
161. **Oberlin E, Amara A, Bachelier F, Bessia C, Virelizier JL, Arenzana-Seisdedos F, Schwartz O, Heard JM, Clark-Lewis I, Legler DF, Loetscher M, Baggiolini M, Moser B.** The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Erratum in: *Nature* 1996; 384:288. *Nature.* 1996; **382**:833-5.
162. **Ogata S, Misumi Y, Ikehara Y.** Primary structure of rat liver dipeptidyl peptidase IV deduced from its cDNA and identification of the NH2-terminal signal sequence as the membrane-anchoring domain. *J Biol Chem.* 1989; **264**:3596-601.
163. **Ohtsuki T, Hosono O, Kobayashi H, Munakata Y, Souta A, Shioda T, Morimoto C.** Negative regulation of the anti-human immunodeficiency virus and chemotactic activity of human stromal cell-derived factor 1alpha by CD26/dipeptidyl peptidase IV. *FEBS Lett.* 1998; **431**:236-40.
164. **Oravecz T, Pall M, Roderiquez G, Gorrell MD, Ditto M, Nguyen NY, Boykins R, Unsworth E, Norcross MA.** Regulation of the receptor specificity and function of the chemokine RANTES (regulated on activation, normal T cell expressed and secreted) by dipeptidyl peptidase IV (CD26)-mediated cleavage. *J Exp Med.* 1997; **186**:1865-72.
165. **Oravecz T, Roderiquez G, Koffi J, Wang J, Ditto M, Bou-Habib DC, Lusso P, Norcross MA.** CD26 expression correlates with entry, replication and cytopathicity of monocytotropic HIV-1 strains in a T-cell line. *Nat Med.* 1995; **1**:919-26.
166. **Ostergaard HL, Shackelford DA, Hurley TR, Johnson P, Hyman R, Sefton BM, Trowbridge IS.** Expression of CD45 alters phosphorylation of the lck-encoded tyrosine protein kinase in murine lymphoma T-cell lines. *Proc Natl Acad Sci U S A.* 1989; **86**:8959-63.
167. **Ostergaard HL, Trowbridge IS.** Co-clustering CD45 with CD4 or CD8 alters the phosphorylation and kinase activity of p56lck. *J Exp Med.* 1990; **172**:347-50.
168. **Papandreou CN, Usmani B, Geng Y, Bogenrieder T, Freeman R, Wilk S, Finstad CL, Reuter VE, Powell CT, Scheinberg D, Magill C, Scher HI, Albino AP, Nanus DM.** Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression. *Nat Med.* 1998; **4**:50-7.
169. **Pauly RP, Demuth HU, Rosche F, Schmidt J, White HA, Lynn F, McIntosh CH, Pederson RA.** Improved glucose tolerance in rats treated with the dipeptidyl peptidase IV (CD26) inhibitor Ile-thiazolidide. *Metabolism.* 1999; **48**:385-9.
170. **Pethiyagoda CL, Welch DR, Fleming TP.** Dipeptidyl peptidase IV (DPPIV) inhibits cellular invasion of melanoma cells. *Clin Exp Metastasis.* 2000; **18**:391-400.
171. **Piazza, G A; Callanan, H M; Mowery, J; Hixson, D C** Evidence for a role of dipeptidyl peptidase IV in fibronectin-mediated interactions of hepatocytes with extracellular matrix. *The Biochemical Journal* 1989; **262**:327-334.
172. **Pineiro-Sanchez ML, Goldstein LA, Dodt J, Howard L, Yeh Y, Tran H, Argraves WS, Chen WT.** Identification of the 170-kDa melanoma membrane-bound gelatinase (seprase) as a serine integral membrane protease. *J Biol Chem.* 1997; **272**:7595-601 (Erratum in: *J Biol Chem.* 1998; **273**:13366).
173. **Proost P, De Meester I, Schols D, Struyf S, Lambeir AM, Wuyts A, Opdenakker G, De Clercq E, Scharpe S, Van Damme J.** Amino-terminal truncation of chemokines by CD26/dipeptidyl-peptidase IV. Conversion of RANTES into a potent inhibitor of monocyte chemotaxis and HIV-1-infection. *J Biol Chem.* 1998; **273**:7222-7.
174. **Proost P, Struyf S, Schols D, Durinx C, Wuyts A, Lenaerts JP, De Clercq E, De Meester I, Van Damme J.** Processing by CD26/dipeptidyl-peptidase IV reduces the chemotactic and anti-HIV-1 activity of stromal-cell-derived factor-1alpha. *FEBS Lett.* 1998; **432**:73-6.
- 174.b **Raisova M, Bektas M, Wieder T, Daniel P, Eberle J, Orfanos CE, Geilen CC.** Resistance to CD95-induced and ceramide-mediated apoptosis of human melanoma cells is caused by a defective mitochondrial cytochrome c release. *FEBS Lett.* 2000; **473**:27-32.

- 174.c **Raisova M, Hossini AM, Eberle J, Riebeling C, Wieder T, Sturm I, Daniel PT, Orfanos CE, Geilker CB.** The CBax/Bcl-2 ratio determines the susceptibility of human melanoma cells to CD95/Fas-mediated apoptosis. *J Invest Dermatol.* 2001; **117**:333-40.
175. **Rasmussen HB, Branner S, Wiberg FC, Wagtmann N.** Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog. *Nat Struct Biol.* 2003; **10**:19-25.
176. **Rawlings ND, Barrett AJ.** Merops: the peptidase database. *Nucleic Acids Res.* 2000; **28**:323-325.
177. **Reimer MK, Holst JJ, Ahren B.** Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice. *Eur J Endocrinol.* 2002; **146**:717-27.
178. **Rettig WJ, Garin-Chesa P, Healey JH, Su SL, Ozer HL, Schwab M, Albino AP, Old LJ.** Regulation and heteromeric structure of the fibroblast activation protein in normal and transformed cells of mesenchymal and neuroectodermal origin. *Cancer Res.* 1993; **53**:3327-35.
179. **Reva B, Finkelstein A, Topiol S.** Threading with chemostructural restrictions method for predicting fold and functionally significant residues: application to dipeptidylpeptidase IV (DPP-IV). *Proteins.* 2002; **47**:180-93.
180. **Ruiz P, Mailhot S, Delgado P, Amador A, Viciana AL, Ferrer L, Zacharievich N.** CD26 expression and dipeptidyl peptidase IV activity in an aggressive hepatosplenic T-cell lymphoma. *Cytometry.* 1998; **34**:30-5.
181. **Salinovich O, Montelaro RC.** Reversible staining and peptide mapping of proteins transferred to nitrocellulose after separation by sodium dodecylsulfate-polyacrylamide gel electrophoresis. *Anal Biochem.* 1986; **156**:341-7.
- 181.b **Sato K, Aytac U, Yamochi T, Yamochi T, Ohnuma K, McKee KS, Morimoto C, Dang NH.** CD26/dipeptidyl peptidase IV enhances expression of topoisomerase II alpha and sensitivity to apoptosis induced by topoisomerase II inhibitors. *Br J Cancer.* 2003; **89**:1366-74.
182. **Schols D, Proost P, Struyf S, Wuyts A, De Meester I, Scharpe S, Van Damme J, De Clercq E.** CD26-processed RANTES(3-68), but not intact RANTES, has potent anti-HIV-1 activity. *Antiviral Res.* 1998; **39**:175-87 (Erratum in: *Antiviral Res* 1999; **40**:189-90).
183. **Schrader WP, West CA, Miczek AD, Norton EK.** Characterization of the adenosine deaminase-adenosine deaminase complexing protein binding reaction. *J Biol Chem.* 1990; **265**:19312-8.
184. **Schrimpf SP, Hellman U, Carlsson L, Larsson A, Ronquist G, Nilsson BO.** Identification of dipeptidyl peptidase IV as the antigen of a monoclonal anti-prostasome antibody. *Prostate.* 1999; **38**:35-9.
185. **Shane R, Wilk S, Bodnar RJ.** Modulation of endomorphin-2-induced analgesia by dipeptidyl peptidase IV. *Brain Res.* 1999; **815**:278-86.
186. **Shimizu Y, Shaw S.** Lymphocyte interactions with extracellular matrix. *FASEB J.* 1991; **5**:2292-9.
187. **Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ, Klenk DC.** Measurement of protein using bicinchoninic acid. *Anal Biochem.* 1985; **150**:76-85 (Erratum in *Anal Biochem* 1987; **163**:279).
188. **Smith RE, Talhouk JW, Brown EE, Edgar SE.** The significance of hypersialylation of dipeptidyl peptidase IV (CD26) in the inhibition of its activity by Tat and other cationic peptides. CD26: a subverted adhesion molecule for HIV peptide binding. *AIDS Res Hum Retroviruses.* 1998; **14**:851-68.
189. **Sorg C, Bruggen J, Seibert E, Macher E.** Membrane-associated antigens of human malignant melanoma. *Cancer Immunol Immunother.* 1978; **3**:259.
190. **Stecca BA, Nardo B, Chieco P, Mazziotti A, Bolondi L, Cavallari A.** Aberrant dipeptidyl peptidase IV (DPPIV/CD26) expression in human hepatocellular carcinoma. *J Hepatol* 1997; **27**:337-345.
191. **Steck G. et al.** Detection of basic proteins and low molecular weight peptides in polyacrylamide gels by formaldehyde fixation. *Anal. Biochem.* 1980; **107**:21-24.
192. **Stegg C, Hartwig U, Fleischer B.** Unchanged signaling capacity of mutant CD26/dipeptidylpeptidase IV molecules devoid of enzymatic activity. *Cell Immunol.* 1995; **164**:311-5.
193. **Struyf S, Menten P, Lenaerts JP, Put W, D'Haese A, De Clercq E, Schols D, Proost P, Van Damme J.** Diverging binding capacities of natural LD78beta isoforms of macrophage inflammatory protein-1alpha to the CC chemokine receptors 1, 3 and 5 affect their anti-HIV-1

- activity and chemotactic potencies for neutrophils and eosinophils. *Eur J Immunol.* 2001; **31**:2170-8.
194. **Tan EY, Mujoondar M, Blay J.** Adenosine down-regulates the surface expression of dipeptidyl peptidase IV on HT-29 human colorectal carcinoma cells: implications for cancer cell behavior. *AM J Pathol.* 2004; **165**(1):319-330.
 195. **Tanaka T, Camerini D, Seed B, Torimoto Y, Dnag NH, Kameoka J, Dahlberg NH, Schlossman SF, Morimoto C.** Cloning and functional expression of the T cell activation antigen CD26. *J Immunol* 1992; **149**:481-486 (Erratum in *J Immunol* 1993; **150**:2090).
 196. **Tanaka T, Duke-Cohan JS, Kameoka J, Yaron A, Lee I, Schlossman SF, Morimoto C.** Enhancement of antigen-induced T-cell proliferation by soluble CD26/dipeptidyl peptidase IV. *Proc Natl Acad Sci U S A.* 1994; **91**:3082-6.
 197. **Tanaka T, Kameoka J, Yaron A, Schlossman SF, Morimoto C.** The costimulatory activity of the CD26 antigen requires dipeptidyl peptidase IV enzymatic activity. *Proc Natl Acad Sci U S A.* 1993; **90**:4586-90.
 198. **Torimoto, Y; Dang, NH; Vivier, E; Tanaka, T; Schlossmann, SF; Morimoto, C** Coassociation of CD26 (dipeptidyl peptidase IV) with CD45 on the surface of human T lymphocytes. *Journal Of Immunology* 1991; **147**:2514-2517.
 199. **Towbin H, Staehelin T, Gordon J.** Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. *Proc Natl Acad Sci USA.* 1979; **76**:4350-4.
 200. **Ulmer AJ, Mattern T, Feller AC, Heymann E, Flad HD.** CD26 antigen is a surface dipeptidyl peptidase IV (DPP-IV) as characterized by monoclonal antibodies clone TII-19-4-7 and 4EL1C7. *Scand J Immunol.* 1990; **31**:429-35.
 201. **Valenzuela A, Blanco J, Callebaut C, Jacotot E, Lluís C, Hovanessian AG, Franco R.** Adenosine deaminase binding to human CD26 is inhibited by HIV-1 envelope glycoprotein gp120 and viral particles. *J Immunol.* 1997; **158**:3721-9.
 202. **Van den Oord JJ.** Expression of CD26/dipeptidyl-peptidase IV in benign and malignant pigment-cell lesions of the skin. *Br J Dermatol.* 1998; **138**:615-21.
 203. **Vanham G, Kestens L, De Meester I, Vingerhoets J, Penne G, Vanhoof G, Scharpe S, Heyligen H, Bosmans E, Ceuppens JL, et al.** Decreased expression of the memory marker CD26 on both CD4+ and CD8+ T lymphocytes of HIV-infected subjects. *J Acquir Immune Defic Syndr.* 1993; **6**:749-57.
 204. **Veillette A, Bookman MA, Horak EM, Samelson LE, Bolen JB.** Signal transduction through the CD4 receptor involves the activation of the internal membrane tyrosine-protein kinase p56lck. *Nature.* 1989; **338**:257-9.
 205. **Verstovsek S, Cabanillas F, Dang NH.** CD26 in T-cell lymphomas: a potential clinical role? *Oncology (Huntingt).* 2000; **14**:17-23.
 206. **Viscidi RP, Mayur K, Lederman HM, Frankel AD.** Inhibition of antigen-induced lymphocyte proliferation by Tat protein from HIV-1. *Science.* 1989; **246**:1606-8.
 207. **Vlasak R, Vilas U, Strobl B, Kreil G.** cDNA cloning and expression of secreted *Xenopus laevis* dipeptidyl aminopeptidase IV. *Eur J Biochem.* 1997; **247**:107-13.
 208. **Vorisek J.** Ultracytochemical localization of X-prolyl-dipeptidyl (amino)peptidase in microglobules and endoplasmic membranes accumulated in pep4-3 mutant of *Saccharomyces cerevisiae*. *Histochemistry.* 1986; **84**:87-96.
 209. **Von Bonin A, Steeg C, Mittrucker HW, Fleischer B.** The T-cell receptor associated zeta-chain is required but not sufficient for CD26 (dipeptidylpeptidase IV) mediated signaling. *Immunol Lett.* 1997; **55**:179-82.
 210. **Werb Z.** ECM and cell surface proteolysis: regulating cellular ecology. *Cell.* 1997; **91**:439-42.
 211. **Wesley U.V.; Albino A.P.; Tiwari S.; Houghton A.N.** A role for dipeptidyl peptidase IV in suppressing the malignant phenotype of melanocytic cells *Journal of Experimental Medicine* 1999; **190**:311-322.
 212. **Wesley UV, Tiwari S, Houghton AN.** Role for dipeptidyl peptidase IV in tumor suppression of human non small cell lung carcinoma cells. In *J Cancer.* 2004; **109**(6):855-866.
 213. **Wiedeman PE, Trevillyan JM.** Dipeptidyl peptidase IV inhibitors for the treatment of impaired glucose tolerance and type 2 diabetes. *Curr Opin Investig Drugs.* 2003; **4**:412-20.

214. **Willheim M, Ebner C, Baier K, Kern W, Schrottbauer K, Thien R, Kraft D, Breiteneder H, Reinisch W, Scheiner O.** Cell surface characterization of T lymphocytes and allergen-specific T cell clones: correlation of CD26 expression with T(H1) subsets. *J Allergy Clin Immunol.* 1997; **100**:348-55.
215. **Wu L, Paxton WA, Kassam N, Ruffing N, Rottman JB, Sullivan N, Choe H, Sodroski J, Newman W, Koup RA, Mackay CR.** CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro. *J Exp Med.* 1997; **185**:1681-91.
216. **Yamamoto K, Yamamoto M.** *Exp. Cell Res.* 1994; **214**:258–263.
- 216.b **Yamochi T, Yamochi T, Aytac U, Sato T, Sato K, Ohnuma K, McKee KS, Morimoto C, Dang NH.** Regulation of p38 phosphorylation and topoisomerase IIalpha expression in the B-cell lymphoma line Jiyoye by CD26/dipeptidyl peptidase IV is associated with enhanced in vitro and in vivo sensitivity to doxorubicin. *Cancer Res.* 2005; **65**:1973-83.
217. **Yan Shuling, Marguet Didier, Dobers Jörg, Reutter Werner and Fan Hua.** Deficiency of CD26 results in a change of cytokine and immunoglobulin secretion after stimulation by pokeweed mitogen. *Eur. J. Immunol.* 2003, **33**:1519-1527.
218. **Young GP, Macrae FA, Gibson PR, Alexeyeff M, Whitehead RH.** Brush border hydrolases in normal and neoplastic colonic epithelium. *J Gastroenterol Hepatol.* 1992; **7**:347-354.
219. **Zoro P, Vassko V, Garcia S, Pazart L, Aho S, De Micco C.** Tumor markers in the cytodagnosis of thyroid nodules. Detection of dipeptidyl aminopeptidase IV (DAPIV) activity. *Ann Pathol.* 1996; **16**:261-265.